‘‘(C) a robust hepatitis surveillance infra-
structure to provide for timely and accurate in-
formation regarding progress to eliminate viral 
hepatitis. 
‘‘(2) REPORT.—An entity that receives a grant 
or cooperative agreement under paragraph (1) shall 
submit to the Secretary, at a time specified by the 
Secretary, a report describing each activity carried 
out pursuant to such paragraph and evaluating the 
effectiveness of such activity in promoting prevention 
and treatment of liver cancer and other liver dis-
eases. 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For purposes of carrying out this subsection, there 
is authorized to be appropriated $90,000,000 for 
each of fiscal years 2022 through 2026. Any 
amounts appropriated under this paragraph shall re-
main available until expended and shall be used to 
supplement and not supplant other Federal funds 
provided for activities under this subsection. 
‘‘(b) AWARENESS INITIATIVE GRANT PROGRAM.— 
‘‘(1) IN
GENERAL.—The Secretary, acting 
through the Director of the Centers for Disease 
Control and Prevention, may award grants to eligi-
ble entities for the purpose of raising awareness for 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
liver cancer and other liver diseases, which may in-
clude the production, dissemination, and distribution 
of informational materials targeted towards commu-
nities and populations with a higher risk for devel-
oping liver cancer and other liver diseases. 
‘‘(2) ELIGIBLE ENTITIES.—To be eligible to re-
ceive a grant under paragraph (1), an entity shall 
submit to the Secretary an application, at such time, 
in such manner, and containing such information as 
the Secretary may require, including a description of 
how the entity, in disseminating information on liver 
cancer and other liver diseases pursuant to para-
graph (1), will— 
‘‘(A) with respect to any community or 
population, consult with members of such com-
munity or population and provide such informa-
tion in a manner that is culturally and linguis-
tically appropriate for such community or popu-
lation; 
‘‘(B) highlight the range of treatments 
available for liver cancer and other liver dis-
eases; 
‘‘(C) integrate information on available 
hepatitis B and hepatitis C testing programs 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
into any liver cancer presentations carried out 
by the entity; and 
‘‘(D) target communities and populations 
with a higher risk for contracting liver cancer 
and other liver diseases. 
‘‘(3) PREFERENCE.—In awarding grants under 
paragraph (1), the Secretary shall give preference to 
entities that— 
‘‘(A) are, or work with, a Federally-quali-
fied health center; or 
‘‘(B) are community-based organizations. 
‘‘(4) REPORT.—An entity that receives a grant 
under paragraph (1) shall submit to the Secretary, 
at a time specified by the Secretary, a report de-
scribing each activity carried out pursuant to such 
paragraph and evaluating the effectiveness of such 
activity in raising awareness for liver cancer and 
other liver diseases. 
‘‘(5) AUTHORIZATION
OF
APPROPRIATIONS.— 
For purposes of carrying out this subsection, there 
is authorized to be appropriated $10,000,000 for 
each of fiscal years 2022 through 2026. Any 
amounts appropriated under this paragraph shall re-
main available until expended and shall be used to 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
supplement and not supplant other Federal funds 
provided for activities under this subsection.’’. 
SEC. 5. HEPATITIS B RESEARCH. 
Subpart 3 of part C of title IV of the Public Health 
Service Act (42 U.S.C. 285c et seq.) is amended by adding 
at the end the following new section: 
‘‘SEC. 434B. HEPATITIS B. 
‘‘The Director of the Institute shall, in collaboration 
with the Director of the National Institute of Allergy and 
Infectious Diseases, issue targeted calls for hepatitis B re-
search proposals focused on key research questions identi-
fied by the research community and discussed in peer-re-
viewed research journal articles.’’. 
SEC. 6. CHANGES RELATING TO NATIONAL INSTITUTE OF 
DIABETES AND DIGESTIVE AND KIDNEY DIS-
EASES. 
(a) CHANGE OF NAME OF NATIONAL INSTITUTE OF 
DIABETES AND DIGESTIVE AND KIDNEY DISEASES.— 
(1) IN GENERAL.—Subpart 3 of part C of title 
IV of the Public Health Service Act (42 U.S.C. 285c 
et seq.) is amended in the subpart heading by strik-
ing ‘‘National Institute of Diabetes and Di-
gestive and Kidney Diseases’’ and inserting 
‘‘National Institute of Diabetes and Diges-
tive, Kidney, and Liver Diseases’’. 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
(2) TREATMENT OF DIRECTOR OF NATIONAL 
INSTITUTE OF DIABETES AND DIGESTIVE AND KID-
NEY DISEASES.—The individual serving as the Di-
rector of the National Institute of Diabetes and Di-
gestive and Kidney Diseases as of the date of enact-
ment of this Act may continue to serve as the Direc-
tor of the National Institute of Diabetes and Diges-
tive, Kidney, and Liver Diseases commencing as of 
that date. 
(3) REFERENCES.—Any reference to the Na-
tional Institute of Diabetes and Digestive and Kid-
ney Diseases, or the Director of the National Insti-
tute of Diabetes and Digestive and Kidney Diseases, 
in any law, regulation, document, record, or other 
paper of the United States shall be deemed to be a 
reference to the National Institute of Diabetes and 
Digestive, Kidney, and Liver Diseases, or the Direc-
tor of the National Institute of Diabetes and Diges-
tive, Kidney, and Liver Diseases, respectively. 
(4) CONFORMING AMENDMENTS.— 
(A) Section 401(b)(3) of the Public Health 
Service Act (42 U.S.C. 281(b)(3)) is amended 
by striking ‘‘The National Institute of Diabetes 
and Digestive and Kidney Diseases.’’ and in-
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
serting ‘‘The National Institute of Diabetes and 
Digestive, Kidney, and Liver Diseases.’’. 
(B) Section 409A(a) of the Public Health 
Service Act (42 U.S.C. 284e(a)) is amended by 
striking ‘‘the National Institute of Diabetes and 
Digestive and Kidney Diseases’’ and inserting 
‘‘the National Institute of Diabetes and Diges-
tive, Kidney, and Liver Diseases’’. 
(b) PURPOSE OF THE INSTITUTE.—Section 426 of 
the Public Health Service Act (42 U.S.C. 285c) is amend-
ed— 
(1) by striking ‘‘National Institute of Diabetes 
and Digestive and Kidney Diseases’’ and inserting 
‘‘National Institute of Diabetes and Digestive, Kid-
ney, and Liver Diseases’’; and 
(2) by striking ‘‘and kidney, urologic, and hem-
atologic diseases’’ and inserting ‘‘kidney, urologic, 
and hematologic diseases, and liver diseases’’. 
(c) DATA SYSTEMS AND INFORMATION CLEARING-
HOUSES.—Section 427 of the Public Health Service Act 
(42 U.S.C. 285c–1) is amended by adding at the end the 
following new subsection: 
‘‘(d) The Director of the Institute shall (1) establish 
the National Liver Diseases Data System for the collec-
tion, storage, analysis, retrieval, and dissemination of data 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
derived from patient populations with liver diseases, in-
cluding, where possible, data involving general populations 
for the purpose of detection of individuals with a risk of 
developing liver diseases, and (2) establish the National 
Liver Diseases Information Clearinghouse to facilitate and 
enhance knowledge and understanding of liver diseases on 
the part of health professionals, patients, and the public 
through the effective dissemination of information.’’. 
(d) REESTABLISHMENT
OF LIVER DISEASE RE-
SEARCH BRANCH WITHIN DIVISION OF DIGESTIVE DIS-
EASES
AND NUTRITION
AS DIVISION
OF LIVER DIS-
EASES.— 
(1) IN GENERAL.—The Liver Disease Research 
Branch within the Division of Digestive Diseases 
and Nutrition of the National Institute of Diabetes 
and Digestive and Kidney Diseases (referred to in 
this subsection as the ‘‘Liver Disease Research 
Branch’’) is hereby redesignated and promoted as 
the Division of Liver Diseases, which shall be within 
the National Institute of Diabetes and Digestive, 
Kidney, and Liver Diseases, as redesignated by sub-
section (a), as a separate division from the other di-
visions within such Institute. 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
(2) DIVISION DIRECTOR.—Section 428 of the 
Public Health Service Act (42 U.S.C. 285c–2) is 
amended— 
(A) in the section heading, by striking 
‘‘DIVISION DIRECTORS FOR DIABETES, EN-
DOCRINOLOGY, 
AND
METABOLIC
DIS-
EASES, DIGESTIVE DISEASES AND NUTRI-
TION, AND KIDNEY, UROLOGIC, AND HEM-
ATOLOGIC DISEASES’’ and inserting ‘‘DIVI-
SION
DIRECTORS
FOR
DIABETES, ENDO-
CRINOLOGY, AND
METABOLIC
DISEASES, 
DIGESTIVE
DISEASES
AND
NUTRITION, 
KIDNEY, UROLOGIC, AND
HEMATOLOGIC 
DISEASES, AND LIVER DISEASES’’; 
(B) in subsection (a)(1)— 
(i) in the matter preceding subpara-
graph (A), by striking ‘‘and a Division Di-
rector for Kidney, Urologic, and Hemato-
logic Diseases’’ and inserting ‘‘a Division 
Director for Kidney, Urologic, and Hem-
atologic Diseases, and a Division Director 
for Liver Diseases’’; and 
(ii) in subparagraph (A), by striking 
‘‘and kidney, urologic, and hematologic dis-
eases’’ and inserting ‘‘kidney, urologic, and 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
hematologic diseases, and liver diseases’’; 
and 
(C) in subsection (b)— 
(i) in the matter preceding paragraph 
(1), by striking ‘‘and the Division Director 
for Kidney, Urologic, and Hematologic 
Diseases’’ and inserting ‘‘the Division Di-
rector for Kidney, Urologic, and Hemato-
logic Diseases, and the Division Director 
for Liver Diseases’’; and 
(ii) in paragraph (1), by striking ‘‘and 
kidney, urologic, and hematologic diseases’’ 
and inserting ‘‘kidney, urologic, and hem-
atologic diseases, and liver diseases’’. 
(3) TREATMENT OF DIRECTOR OF LIVER DIS-
EASE RESEARCH BRANCH.—The individual serving 
as the Director of the Liver Disease Research 
Branch as of the date of enactment of this Act may 
continue to serve as the Division Director for Liver 
Diseases commencing as of that date. 
(4) TRANSFER
OF
AUTHORITIES.—The Sec-
retary of Health and Human Services shall delegate 
to the Division Director for Liver Diseases all duties 
and authorities that were vested in the Director of 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
the Liver Disease Research Branch as of the day be-
fore the date of enactment of this Act. 
(5) REFERENCES.—Any reference to the Liver 
Disease Research Branch, or the Director of the 
Liver Disease Research Branch, in any law, regula-
tion, document, record, or other paper of the United 
States shall be deemed to be a reference to the Divi-
sion of Liver Diseases, or the Division Director for 
Liver Diseases, respectively. 
(e) INTERAGENCY COORDINATING COMMITTEES.— 
Section 429(a) of the Public Health Service Act (42 
U.S.C. 285c–3(a)) is amended— 
(1) in paragraph (1), by striking ‘‘and kidney, 
urologic, and hematologic diseases’’ and inserting 
‘‘kidney, urologic, and hematologic diseases, and 
liver diseases’’; and 
(2) in the matter following paragraph (2), by 
striking ‘‘and a Kidney, Urologic, and Hematologic 
Diseases Coordinating Committee’’ and inserting ‘‘a 
Kidney, Urologic, and Hematologic Diseases Coordi-
nating Committee, and a Liver Diseases Coordi-
nating Committee’’. 
(f) ADVISORY BOARDS.—Section 430 of the Public 
Health Service Act (42 U.S.C. 285c–4) is amended— 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
(1) in subsection (a), by striking ‘‘and the Na-
tional Kidney and Urologic Diseases Advisory 
Board’’ and inserting ‘‘the National Kidney and 
Urologic Diseases Advisory Board, and the Liver 
Diseases Advisory Board’’; and 
(2) in subsection (b)(2)(A)(i)— 
(A) by striking ‘‘the Director of the Na-
tional Institute of Diabetes and Digestive and 
Kidney Diseases’’ and inserting ‘‘the Director 
of the National Institute of Diabetes and Diges-
tive, Kidney, and Liver Diseases’’; and 
(B) by striking ‘‘and the Division Director 
of the National Institute of Diabetes and Diges-
tive and Kidney Diseases’’ and inserting ‘‘and 
the Division Director of the National Institute 
of Diabetes and Digestive, Kidney, and Liver 
Diseases’’. 
(g) RESEARCH AND TRAINING CENTERS.—Section 
431 of the Public Health Service Act (42 U.S.C. 285c– 
5) is amended— 
(1) by redesignating subsection (e) as sub-
section (f); and 
(2) by inserting after subsection (d) the fol-
lowing new subsection: 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS
‘‘(e) The Director of the Institute shall provide for 
the development or substantial expansion of centers for 
research in liver diseases. Each center developed or ex-
panded under this subsection— 
‘‘(1) shall utilize the facilities of a single insti-
tution, or be formed from a consortium of cooper-
ating institutions, meeting such research qualifica-
tions as may be prescribed by the Secretary; 
‘‘(2) shall develop and conduct basic and clin-
ical research into the cause, diagnosis, early detec-
tion, prevention, control, and treatment of liver dis-
eases and related functional, congenital, metabolic, 
or other complications resulting from such diseases; 
‘‘(3) shall encourage research into and pro-
grams for— 
‘‘(A) providing information for patients 
with such diseases and complications and the 
families of such patients, physicians and others 
who care for such patients, and the general 
public; 
‘‘(B) model programs for cost effective and 
preventive patient care; and 
‘‘(C) training physicians and scientists in 
research on such diseases and complications; 
and 
VerDate Sep 11 2014 
04:35 Oct 28, 2021
Jkt 029200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H5675.IH
H5675
kjohnson on DSK79L0C42PROD with BILLS